This review highlights the critical role of cardio-oncology in identifying, preventing, and managing cancer therapy-induced cardiotoxicity to improve patient prognosis and quality of care.
Answers are grounded in this paper and cite their sources.
May guide cardio-oncology monitoring in cancer patients; leaves open standardized protocols for imaging and prevention.
Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing cardiovascular morbidity and mortality and improving quality of life in cancer survivors. Cancer survival rates have been constantly increasing, mainly because of the advent of new, more potent and targeted therapies. However, many of the new therapies - along with some of the older chemotherapeutic regimens such as anthracyclines - are potentially cardiotoxic, which is reflected increasingly frequently in the published literature. Cardiotoxicity adversely affects prognosis in cancer patients, thus its prevention and treatment are crucial to improve quality and standards of care. This review aims to explore the existing literature relating to chemotherapy- and radiotherapy-induced cardiotoxicity. An overview of the imaging modalities for the identification of cardiotoxicity and therapies for its prevention and management is also provided.
No takes yet. Share an insight, caveat, or question.
Koutsoukis et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: